ReviewCancer journal (Sudbury, Mass.)
Prognostic determinants in prostate cancer.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Present status of prostate cancer diagnosis, limitations, challenges, and future endeavors.Annals of medicine · 2026Review
- HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Immunohistochemical Evidence of Telocytic Stroma Associated with Tumor Grade and Acinar Heterogeneity in Prostate Cancer.International journal of molecular sciences · 2026Article
- Peritumoral CD117 Immunopositive Mast Cell Density in Prostatic Adenocarcinoma and Its Correlation with the New Gleason Score.Indian journal of surgical oncology · 2025Article
- Evaluation of potential prognostic significance of JUNB in human prostate cancer: a bioinformatic and histopathological study.Journal of pathology and translational medicine · 2025Article
- From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.Health information science and systems · 2024Review
- Article
- Application of Spectral Algorithm Applied to Spatially Registered Bi-Parametric MRI to Predict Prostate Tumor Aggressiveness: A Pilot Study.Diagnostics (Basel, Switzerland) · 2023Article
- Glycyl-tRNA Synthetase (GARS) Expression Is Associated with Prostate Cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.International journal of molecular sciences · 2023Article
- Combining and analyzing novel multi-parametric magnetic resonance imaging metrics for predicting Gleason score.Quantitative imaging in medicine and surgery · 2022Article
- Article
- Development and testing quantitative metrics from multi-parametric magnetic resonance imaging that predict Gleason score for prostate tumors.Quantitative imaging in medicine and surgery · 2022Article
- Prostate tumor eccentricity predicts Gleason score better than prostate tumor volume.Quantitative imaging in medicine and surgery · 2022Article
- Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in Prostate Carcinoma Patients.BioMed research international · 2022Article
- Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.American journal of cancer research · 2022Article
- Prostate cancer-associated urinary proteomes differ before and after prostatectomy.Therapeutic advances in medical oncology · 2022Article
- Assessing and testing anomaly detection for finding prostate cancer in spatially registered multi-parametric MRI.Frontiers in oncology · 2022Article
- Updates on Molecular and Biochemical Development and Progression of Prostate Cancer.Journal of clinical medicine · 2021Review
- Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.Frontiers in genetics · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Clinical outcomes in prostate cancer are heterogeneous, and given the high prevalence of the disease, there is a pressing need to identify clinically useful markers of prognosis. Many clinical, pathological, molecular, and genetic factors have been investigated in this capacity, although relatively few are routinely used. With a growing understanding of the molecular pathogenesis of prostate cancer, there is the potential that the next generation of makers will prove sufficiently robust to guide the optimal management of men with prostate cancer. Here, we review the various clinical and molecular prognostic determinants in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.